BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
Release time:
2017-08-30
BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market.
BrosMed Medical Announces Japanese Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market
Aug 30th , 2017—BrosMed Medical announces Japan PMDA approval of its Artimes™ and Apollo™ PTCA balloons, marking its formal commercial launch in Japan. Artimes™ and Apollo™ are two PTCA of Brosmed balloon families. Artimes™ is a semi-compliant pre-dilatation PTCA balloon, and Apollo™ is a non-complaint high pressure post-dilatation PTCA balloon. These two balloons are designed for the treatment of percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries.
Following the approval, BrosMed Medical achieves one more step to its global vision beside current geographical footprint in Europe, USA, China, Asia Pacific, Latin America and Middle East.
“The PMDA approval of Artimes™ and Apollo™ PTCA in Japan is quite exciting and significant to the company.” said by Stephen Lee, General Manager of BrosMed Medical. “PMDA approval helps BrosMed to penetrate the Japan market and compete ourselves with giant companies and local players in term of products performance and services. We are confident that Artimes™ and Apollo™ would satisfy Japanese physicians’ needs and provide better clinical outcomes. Moreover, we are going to provide our completed PTA portfolio to the Japan market as second step in order to expand us from cardiovascular to endovascular filed.”
Please contact our regional distributors and/or our sales at sales@brosmed.com for more products details.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
BrosMed Medical product portfolio consist of Artimes™ PTCA, Apollo™NC PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wireandFreepath™ Catheter Sheath Introducer. BrosMed Medical is supplying safe, effective and hi-tech medical devices in 30 countries.
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
